Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US7560425B2 · kind B2 · utility
3Cited by
8References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2003 |
| Grant date | Jul 14, 2009 |
| Priority date | — |
| Expiry date | Jun 21, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.